New clinical findings further reinforce therapeutic potential of vapendavir as targeted approach to preventing rhinovirus-driven COPD exacerbations WASHINGTON, June 5, 2026 /PRNewswire/ — Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, today presented new clinical findings demonstrating vapendavir, an investigational oral rhinovirus capsid [...]